References
- Omalizumab (Xolair) label. Novartis US, Genentech, July 2010. Available at: www.gene.com/gene/products/information/pdf/xolair-prescribing.pdf [Last accessed 25 April 2013]
- Omalizumab (XOLAIR). Summary of product characteristics. European Medicines Agency (EMA), 2012. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000606/WC500057298.pdf [Last accessed 25 April 2013]
- Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302-8
- Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309-16
- Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009;39:788-97
- Molimard M, de Blay F, Didier A, et al. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008;102:71-6
- Brusselle G, Michils A, Louis R, et al. ‘Real-life’ effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009;103:1633-42
- Korn S, Thielen A, Seyfried S, et al. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009;103:1725-31
- Korn S, Schumann C, Kropf C, et al. Effectiveness of omalizumab in patients 50 years and older with severe persistent allergic asthma. Ann Allergy Asthma Immunol 2010;105:313-19
- Omalizumab (XOLAIR). Summary of product characteristics (2010). European Medicines Agency. Available at: www.ema.europa.eu [Last accessed 25 April 2013]
- Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-lgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997;100:110-21
- Sampson HA, Munoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006;117:391-7
- Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. EMEA/CHMP/BMWP/42832/2005. European Medicines Agency (EMA), 2006. Available at: www.ema.europa.eu [Last accessed 25 April 2013]
- FDA guidance concerning demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. US Food and Drug Administration, 1996. Available at: www.fda.gov/ohrms/dockets/dockets/80n0208/80n-0208-bkg0006-10-Ref-08-FDA-Guidance-vol225.pdf [Last accessed 25 April 2013]
- Schellekens H. Follow-on biologics: challenges of the ‘next generation’. Nephrol Dial Transplant 2005;20(Suppl 4):iv31-6
- Haselbeck A. Epoetins: differences and their relevance to immunogenicity. Curr Med Res Opin 2003;19:430-2
- Rivière GJ, Yeh CM, Reynolds CV, et al. Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation. J Bioequiv Availab 2011;3:144-50